Correction: Regulation of Aldo-keto-reductase family 1 B10 by 14-3-3ε and their prognostic impact of hepatocellular carcinoma

Tzu-An Liu; Yee-Jee Jan; Bor-Sheng Ko; Yi-Ju Wu; Yi-Jhu Lu; Shu-Man Liang; Chia-Chia Liu; Shyh-Chang Chen; John Wang; Song-Kun Shyue; Jun-Yang Liou

doi:10.18632/oncotarget.26226

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Regulation of Aldo-keto-reductase family 1 B10 by 14-3-3ε and their prognostic impact of hepatocellular carcinoma

PDF | How to cite

Oncotarget. 2018; 9:35026-35026. https://doi.org/10.18632/oncotarget.26226

Metrics: PDF 1393 views | ?

Tzu-An Liu^1,*, Yee-Jee Jan^2,*, Bor-Sheng Ko^3,*, Yi-Ju Wu^1,4,*, Yi-Jhu Lu¹, Shu-Man Liang¹, Chia-Chia Liu¹, Shyh-Chang Chen², John Wang², Song-Kun Shyue⁵ and Jun-Yang Liou^1,6

¹ Institute of Cellular and System Medicine, National Health Research Institutes, Zhunan 350, Taiwan
² Department of Pathology and Laboratory Medicine, Taichung Veterans General Hospital, Taichung 407, Taiwan
³ Department of Internal Medicine, National Taiwan University Hospital, Taipei 100, Taiwan
⁴ Institute of Molecular Medicine, National Tsing Hua University, Hsinchu 300, Taiwan
⁵ Institute of Biomedical Sciences, Academia Sinica, Taipei 115, Taiwan
⁶ Graduate Institute of Basic Medical Science, China Medical University, Taichung 404, Taiwan
^* These authors contributed equally to this work

Published: October 09, 2018

This article has been corrected: The labelling for equal first authorship is given below:

^* These authors contributed equally to this work

Original article: Oncotarget. 2015; 6:38967-38982. DOI: https://doi.org/10.18632/oncotarget.5734.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26226

Publication Alerts

Corrections:

Correction: Regulation of Aldo-keto-reductase family 1 B10 by 14-3-3ε and their prognostic impact of hepatocellular carcinoma